JP2022523710A5 - - Google Patents
Info
- Publication number
- JP2022523710A5 JP2022523710A5 JP2021544141A JP2021544141A JP2022523710A5 JP 2022523710 A5 JP2022523710 A5 JP 2022523710A5 JP 2021544141 A JP2021544141 A JP 2021544141A JP 2021544141 A JP2021544141 A JP 2021544141A JP 2022523710 A5 JP2022523710 A5 JP 2022523710A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cdr2
- cdr1
- optionally
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019073402 | 2019-01-28 | ||
| CNPCT/CN2019/073402 | 2019-01-28 | ||
| PCT/US2020/014425 WO2020159754A2 (en) | 2019-01-28 | 2020-01-21 | Antibodies specific to cd44 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523710A JP2022523710A (ja) | 2022-04-26 |
| JP2022523710A5 true JP2022523710A5 (enExample) | 2023-02-01 |
| JP7656330B2 JP7656330B2 (ja) | 2025-04-03 |
Family
ID=71840370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544141A Active JP7656330B2 (ja) | 2019-01-28 | 2020-01-21 | Ｃｄ４４に特異的な抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12311031B2 (enExample) |
| EP (1) | EP3917952A4 (enExample) |
| JP (1) | JP7656330B2 (enExample) |
| CN (1) | CN113474362B (enExample) |
| AU (1) | AU2020216780B2 (enExample) |
| TW (1) | TWI870378B (enExample) |
| WO (1) | WO2020159754A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023024623A2 (pt) * | 2021-05-28 | 2024-02-20 | Nsk Ltd | Método de detecção do estado de dispositivo de rolamento, dispositivo de detecção e programa |
| CN114213538B (zh) * | 2021-12-24 | 2022-07-08 | 北京市神经外科研究所 | Cd44抗体、嵌合抗原受体及其应用 |
| CN114316049B (zh) * | 2021-12-24 | 2022-08-09 | 北京市神经外科研究所 | Cd44抗体、嵌合抗原受体及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| KR20250080903A (ko) * | 2022-10-19 | 2025-06-05 | 멀티튜드 테라퓨틱스 인코퍼레이티드 | 항체-약물 접합체, 이의 제조 방법 및 용도 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0767379A1 (de) * | 1993-06-22 | 1997-04-09 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Diagnose und Analyse von Kolonkarzinomen |
| AU2004289265A1 (en) * | 2003-11-07 | 2005-05-26 | Brigham And Women's Hospital, Inc. | Antibodies to CD44 glycoforms and uses thereof |
| WO2006076021A2 (en) * | 2004-05-07 | 2006-07-20 | University Of Florida Research Foundation, Inc. | Cd44 variants as therepeutic targets |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| WO2011022335A1 (en) * | 2009-08-21 | 2011-02-24 | Mount Sinai School Of Medicine Of New York University | Methods of using cd44 fusion proteins to treat cancer |
| LT3194434T (lt) * | 2014-09-15 | 2019-09-25 | Molmed Spa | Chimeriniai antigeno receptoriai |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| BR112018070097A2 (pt) * | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| CN113896793B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
-
2020
- 2020-01-21 AU AU2020216780A patent/AU2020216780B2/en active Active
- 2020-01-21 JP JP2021544141A patent/JP7656330B2/ja active Active
- 2020-01-21 EP EP20747727.4A patent/EP3917952A4/en active Pending
- 2020-01-21 WO PCT/US2020/014425 patent/WO2020159754A2/en not_active Ceased
- 2020-01-21 CN CN202080011128.1A patent/CN113474362B/zh active Active
- 2020-01-21 TW TW109102201A patent/TWI870378B/zh active
-
2021
- 2021-07-27 US US17/386,197 patent/US12311031B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523710A5 (enExample) | ||
| JP2022514693A5 (enExample) | ||
| JP2021531825A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| KR102749049B1 (ko) | 분자를 표적화하기 위한 항원 결합 구조체 | |
| JP2022541435A5 (enExample) | ||
| JP2021531826A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2018532766A5 (enExample) | ||
| JP2012504401A (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2022533538A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2021521793A5 (enExample) | ||
| JP2022542559A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| TW202200618A (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2022514786A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| JP2023524102A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| JP2025026839A5 (enExample) |